Protein / target
Prostate-specific antigen
Protein at a glance
Biological role
Serine-type endopeptidase
Strongest disease association
Prostate carcinoma
Therapeutic position
Established drug target
Research activity
Emerging research
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Hydrolyzes semenogelin-1 thus leading to the liquefaction of the seminal coagulum
Subcellular location
Domains and Gene Ontology detail (16)Hide
Domains & features
Gene Ontology
- Cextracellular exosome
- Cextracellular region
- Cextracellular space
- Cnucleus
- Cprotein-containing complex
- Csecretory granule
- Fendopeptidase activity
- Fhydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides
- Fserine-type endopeptidase activity
- Fserine-type peptidase activity
- Pnegative regulation of angiogenesis
- Ppositive regulation of antibacterial peptide production
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Proteolysis
- ·endopeptidase activity
- ·serine-type endopeptidase activity
- ·serine-type peptidase activity
- ·proteolysis
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene KLK3
Gene-level evidence surfaced through the gene KLK3that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
1 compounds recorded · 1 approved
View all recorded compounds (1)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Emerging
Antibodies — Strong
Protein degraders — Emerging
View underlying tractability evidence (9)Hide
Raw Open Targets tractability assessment buckets, by modality.
Research activity
Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.
Most cited
Recent
Europe PMC papers linked directly to this protein.